Literature DB >> 3143477

Failure of sodium pentobarbital anesthesia to alter 1-desamino-8-D-arginine vasopressin-induced elevations of plasma factor VIII/ von Willebrand factor in normal dogs.

I B Johnstone1, S Crane.   

Abstract

The vasopressin analog 1-desamino-8-D-arginine stimulates elevations in plasma Factor VIII/ von Willebrand factor in normal dogs. In order to study the effects of general anesthesia on this response, six dogs were anesthetized with sodium pentobarbital or given an equivalent amount of saline then challenged with an intravenous dose of 1-desamino-8-D-arginine (0.6 micrograms/kg body weight). Factor VIII coagulant activity, von Willebrand factor antigen, and ristocetin cofactor activity were quantitated before anesthesia (or saline infusion), 20 min after induction (pre-1-desamino-8-D-arginine), and at 30 and 60 min post-1-desamino-8-D-arginine. Anesthesia did not significantly affect the elevations in plasma Factor VIII/ von Willebrand factor induced by 1-desamino-8-D-arginine. Sodium pentobarbital appeared however to prevent the rise in Factor VIII coagulant activity seen following saline treatment. The results of this study suggest that when 1-desamino-8-D-arginine is to be used in normal dogs to boost basal plasma von Willebrand factor levels, it is not necessary to administer it prior to induction of general anesthesia with sodium pentobarbital.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143477      PMCID: PMC1255483     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  14 in total

Review 1.  The factor VIII complex: structure and function.

Authors:  L W Hoyer
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

2.  The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.

Authors:  I B Johnstone; S Crane
Journal:  Can J Vet Res       Date:  1987-04       Impact factor: 1.310

3.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.

Authors:  Z M Ruggeri; P M Mannucci; R Lombardi; A B Federici; T S Zimmerman
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

4.  Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.

Authors:  V Vicente; I Alberca; P M Mannucci
Journal:  Thromb Haemost       Date:  1984-02-28       Impact factor: 5.249

5.  The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.

Authors:  E H Moffat; J C Giddings; A L Bloom
Journal:  Br J Haematol       Date:  1984-08       Impact factor: 6.998

6.  Ristocetin-Willebrand factor activity in dog plasma.

Authors:  I B Johnstone; F Lotz
Journal:  Can J Physiol Pharmacol       Date:  1980-09       Impact factor: 2.273

7.  Determination of Canine Factor VIII-related Antigen Using Commercial Antihuman F VIII Serum.

Authors:  I B Johnstone; S Crane
Journal:  Vet Clin Pathol       Date:  1980       Impact factor: 1.180

8.  Von Willebrand's disease in dogs.

Authors:  W J Dodds
Journal:  Mod Vet Pract       Date:  1984-09

9.  Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.

Authors:  P M Mannucci; M T Canciani; L Rota; B S Donovan
Journal:  Br J Haematol       Date:  1981-02       Impact factor: 6.998

10.  New ways to boost factor VIII in hemophilia: DDAVP for mild hemophilia A, von Willebrand's.

Authors:  C Marwick
Journal:  JAMA       Date:  1983-06-24       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.